Nektar Therapeutics (NASDAQ:NKTR) Price Target Raised to $123.00

Nektar Therapeutics (NASDAQ:NKTR) had its target price increased by Citigroup from $102.00 to $123.00 in a report published on Monday,Benzinga reports. Citigroup currently has a buy rating on the biopharmaceutical company’s stock.

Several other brokerages also recently weighed in on NKTR. Jefferies Financial Group reaffirmed a “buy” rating on shares of Nektar Therapeutics in a report on Wednesday, December 17th. Wall Street Zen downgraded shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. HC Wainwright raised their target price on shares of Nektar Therapeutics from $135.00 to $165.00 and gave the stock a “buy” rating in a research note on Tuesday, February 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $105.00 target price on shares of Nektar Therapeutics in a report on Monday, January 26th. Finally, BTIG Research boosted their price target on shares of Nektar Therapeutics from $118.00 to $151.00 and gave the stock a “buy” rating in a research note on Tuesday, February 10th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $136.43.

Nektar Therapeutics Price Performance

NASDAQ NKTR opened at $73.18 on Monday. The company has a fifty day moving average of $55.29 and a two-hundred day moving average of $54.16. The company has a market capitalization of $1.49 billion, a PE ratio of -7.18 and a beta of 1.17. Nektar Therapeutics has a 1 year low of $6.45 and a 1 year high of $77.00.

Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Thursday, March 12th. The biopharmaceutical company reported ($1.78) EPS for the quarter, topping analysts’ consensus estimates of ($2.69) by $0.91. The business had revenue of $21.81 million for the quarter, compared to analysts’ expectations of $10.44 million. Nektar Therapeutics had a negative return on equity of 386.16% and a negative net margin of 297.07%. On average, research analysts expect that Nektar Therapeutics will post -0.72 earnings per share for the current year.

Insider Buying and Selling at Nektar Therapeutics

In other news, insider Jonathan Zalevsky sold 3,867 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $35.67, for a total transaction of $137,935.89. Following the transaction, the insider directly owned 21,354 shares of the company’s stock, valued at $761,697.18. This represents a 15.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Howard W. Robin sold 423 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $73.00, for a total transaction of $30,879.00. Following the completion of the transaction, the chief executive officer owned 75,489 shares of the company’s stock, valued at $5,510,697. This represents a 0.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 4,470 shares of company stock valued at $181,955 in the last quarter. 5.25% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets lifted its position in shares of Nektar Therapeutics by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 210 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Nektar Therapeutics in the 2nd quarter worth approximately $65,000. Integrated Wealth Concepts LLC purchased a new position in Nektar Therapeutics in the 1st quarter valued at approximately $68,000. Quarry LP purchased a new position in Nektar Therapeutics in the 4th quarter valued at approximately $85,000. Finally, Compass Wealth Management LLC acquired a new position in Nektar Therapeutics during the third quarter worth $88,000. 75.88% of the stock is currently owned by institutional investors and hedge funds.

Key Nektar Therapeutics News

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: TD Cowen initiated coverage with a Buy rating, highlighting upside potential and driving renewed institutional interest. TD Cowen initiates coverage of Nektar Therapeutics (NKTR) with buy recommendation
• Positive Sentiment: Other analysts (Citigroup, H.C. Wainwright, TipRanks summaries) have issued bullish takes or reiterated Buy ratings, citing Rezpeg clinical momentum and a strong cash runway that support upside for indications like atopic dermatitis and alopecia areata. Nektar Therapeutics Stock Price Expected to Rise, Citigroup Analyst Says
• Neutral Sentiment: Technical/fundamental context: NKTR has recently posted an earnings beat (revenue above consensus) and maintains a sizable cash runway, which underpins bullish analyst views even as the name remains volatile versus its 12‑month range.
• Negative Sentiment: A broad wave of class-action filings and law‑firm solicitations allege securities fraud tied to statements about patient enrollment/compliance in the REZOLVE‑AA program; multiple firms (Pomerantz, Levi & Korsinsky, Faruqi & Faruqi, Rosen, Glancy, etc.) have filed or are seeking plaintiffs and remind investors of a May 5, 2026 lead‑plaintiff deadline — this legal overhang is the main near‑term downside catalyst. Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics Levi & Korsinsky investor alert on alleged enrollment issues

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.